Metrion, LifeArc extend neuroscience drug collaboration

By The Science Advisory Board staff writers

January 19, 2021 -- Ion channel contract research organization Metrion Biosciences and U.K. medical research charity LifeArc have extended their neuroscience drug discovery collaboration for 12 months.

Under the terms of the deal, Metrion is providing its ion channel and electrophysiology-based assays and safety profiling services, while LifeArc is working to identify novel modulators of central nervous system ion-channel targets and all new chemical syntheses, according to the companies. Metrion is also utilizing both automated electrophysiology and manual patch clamp technologies to evaluate the pharmacological activities of LifeArc compounds.

An initial agreement between the firms was signed in January 2019 and then extended again in December 2019. After mutually agreed criteria were achieved, LifeArc said it has exercised its option to extend the collaboration for 12 more months.

SARS-CoV-2 envelope protein identified as target for antiviral drugs
Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve...
Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...
Cryo-EM sheds light on ion channel regulation
A long-standing hypothesis about the regulation of ion channels has been confirmed by cryoelectron microscopy (cryo-EM) imaging. The research presented...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter